INT207134

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2007
Last Reported 2008
Negated 0
Speculated 1
Reported most in Body
Documents 11
Total Number 15
Disease Relevance 11.16
Pain Relevance 1.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
mast cell 5
bladder 2
smooth muscle 1
lung 1
heart 1
tryptase (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 266 98.96 Very High Very High Very High
cytokine 30 85.68 High High
Inflammatory mediators 3 82.40 Quite High
substance P 21 65.00 Quite High
agonist 7 64.96 Quite High
Hyperalgesia 2 63.28 Quite High
Inflammatory stimuli 29 58.80 Quite High
Inflammatory response 51 57.24 Quite High
alcohol 8 57.24 Quite High
pruritus 45 53.52 Quite High
Disease Link Frequency Relevance Heat
Myelofibrosis 1 99.96 Very High Very High Very High
Hyperplasia 1 99.06 Very High Very High Very High
INFLAMMATION 343 98.96 Very High Very High Very High
Mastocytosis 448 98.76 Very High Very High Very High
Non-genital Cutaneous Warts 2 98.72 Very High Very High Very High
Heart Rate Under Development 25 98.56 Very High Very High Very High
Microphthalmia 69 97.88 Very High Very High Very High
Carcinoma 24 97.62 Very High Very High Very High
Thrombocytopenia 5 97.34 Very High Very High Very High
Anaemia 5 96.86 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results agree with the findings from the OPA score that mastocytosis patients feel disabled by their symptoms regardless of whether they have CM or SM, that the overall extent of disability does not differ significantly between these two main types of mastocytosis, and that overall disability is unrelated to the presence of the presence of the D816V mutation or an elevated serum tryptase level.
Positive_regulation (elevated) of tryptase associated with cutaneous mastocytosis, systemic mastocytosis and mastocytosis
1) Confidence 0.47 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386235 Disease Relevance 0.96 Pain Relevance 0.03
These findings indicate that the patients' overall perception of disability is unrelated to whether they have an elevated serum tryptase level.


Spec (whether) Positive_regulation (elevated) of tryptase
2) Confidence 0.47 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386235 Disease Relevance 0.40 Pain Relevance 0
The objectives of the current cohort study were to (i) evaluate the patients' perception of disability, (ii) establish and validate a composite score for disability, (iii) determine the most important symptoms causing the patients' perception of disability, and (iv) correlate disability with mastocytosis classification and presence of the D816V KIT mutation and an elevated level of serum tryptase.


Positive_regulation (elevated) of tryptase associated with mastocytosis
3) Confidence 0.44 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386235 Disease Relevance 0.51 Pain Relevance 0
It appears that the presence of elevated mast cell numbers in bone marrow or extracutaneous tissues, an elevated serum tryptase level, and the D816V KIT mutation has little or no bearing on the type or severity symptoms.
Positive_regulation (elevated) of tryptase in mast cell
4) Confidence 0.44 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386235 Disease Relevance 0.55 Pain Relevance 0
Accordingly, we expect that the level of activated, mature tryptase, which is a measure of mast cell activation [14], will be more useful than total serum tryptase for understanding the pathogenesis of mastocytosis.
Positive_regulation (activated) of tryptase in mast cell associated with mastocytosis
5) Confidence 0.44 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386235 Disease Relevance 0.35 Pain Relevance 0
In addition to the J82 cell line, expression of PARs in RT4 bladder papilloma cells was inferred based on findings that RT4 cells respond to activators of PARs such as thrombin, tryptase, and PAR-activating peptides[30].
Positive_regulation (activators) of tryptase in RT4 associated with non-genital cutaneous warts and carcinoma
6) Confidence 0.14 Published 2007 Journal BMC Physiol Section Body Doc Link PMC1853108 Disease Relevance 1.31 Pain Relevance 0.20
However, to the best of our knowledge, there is no information regarding which particular tryptase is expressed in the mouse bladder and/or upregulated in this mouse model during inflammation.
Positive_regulation (upregulated) of tryptase in bladder associated with inflammation
7) Confidence 0.13 Published 2007 Journal BMC Physiol Section Body Doc Link PMC1853108 Disease Relevance 0.28 Pain Relevance 0.20
One group included 13 cases with elevated concentrations of femoral mast cell tryptase (?
Positive_regulation (elevated) of tryptase in mast cell
8) Confidence 0.11 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350147 Disease Relevance 0.12 Pain Relevance 0.03
Moreover, the observation of pulmonary edema and congestion that complicates heroin overdosage, in conjunction with increased postmortem levels of tryptase that hitherto has not been explained, encouraged us to investigate the distribution of infiltrated MCs also in the lung of drug fatalities, and compare with that of the cardiac tissue in the same group versus control group.


Positive_regulation (increased) of tryptase in lung associated with heart rate under development
9) Confidence 0.08 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350147 Disease Relevance 1.26 Pain Relevance 0
The high degree of MC degranulation and the elevated levels of tryptase together with the pathological changes in heart of drug-related victims resemble that of the anaphylactic deaths as demonstrated in our previous study.



Positive_regulation (elevated) of tryptase in heart associated with anaphylaxis
10) Confidence 0.07 Published 2007 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2350147 Disease Relevance 0.97 Pain Relevance 0
In lung sections of drug deaths with high levels of femoral tryptase (HLT), there were higher numbers of infiltrated MC-subsets at the site of bronchial smooth muscle (p < 0.05) and parenchymal tissues compared with the other two groups (Table 4).
Positive_regulation (levels) of tryptase in smooth muscle
11) Confidence 0.07 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350147 Disease Relevance 0.18 Pain Relevance 0.05
The following terms are currently used in medical literature to qualify different patient subsets among those fulfilling the diagnostic criteria of HES:

• FIP1L1-PDGFRA(F/P)-associated HES, or F/P+ HES, for patients with clonal hypereosinophilia due to a sporadic hematopoiëtic stem cell chromosomal rearrangement resulting in fusion of two genes (FIP1L1 and PDGFRA) on 4q12; these patients are more appropriately classified as F/P+ chronic eosinophilic leukemia. • Chronic eosinophilic leukemia (CEL), for patients in whom clonality of eosinophils has been demonstrated (including those with the FIP1L1-PDGFRA fusion), or who present increased blasts; occasional reports indicate that some patients with CEL progress towards acute myeloid or eosinophilic leukemia. • Lymphocytic-HES (L-HES), for patients with chronic reactive (polyclonal) hypereosinophilia secondary to IL-5 over-production by T cells. • Myeloproliferative-HES (M-HES) may be used for patients with an array of clinical and biological features suggesting the possible existence of an underlying myeloproliferative disorder associated with hypereosinophilia, although underlying molecular defects are not detected (including increased serum vitamin B12, hepato- and/or splenomegaly, anemia and/or thrombocytopenia, circulating myeloid precursors, dysplastic eosinophils, bone marrow hypercellularity with left shift in maturation, myelofibrosis, increased serum tryptase, and response to imatinib); this term is occasionally extended more largely to include patients with known molecular defects (e.g.

Positive_regulation (increased) of tryptase in B12 associated with myeloproliferative disorder, anaemia, splenomegaly, hypereosinophilic syndrome, thrombocytopenia, myelofibrosis and hyperplasia
12) Confidence 0.07 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC2045078 Disease Relevance 2.55 Pain Relevance 0
However, to the best of our knowledge, there is no information regarding which particular tryptase is expressed in the mouse bladder and/or upregulated in the mouse model during inflammation.
Positive_regulation (upregulated) of tryptase in bladder associated with inflammation
13) Confidence 0.04 Published 2007 Journal BMC Immunol Section Body Doc Link PMC2000913 Disease Relevance 0.27 Pain Relevance 0.16
Our present findings further emphasize that products of mast cells such as tryptase inducing activation of PARs can lead to increased activity of transcription factors such as TFEB that play a fundamental role in mast cell survival.
Positive_regulation (activation) of tryptase in mast cell
14) Confidence 0.03 Published 2007 Journal BMC Immunol Section Body Doc Link PMC2000913 Disease Relevance 0.70 Pain Relevance 0.25
To the best of our knowledge, this is the first report describing TFEB expression in response to PAR activation in the bladder and suggest a unifying, mechanistic pathway of bladder inflammation as follows: we hypothesize that mast cells release tryptase resulting in increased PAR activation and, consequently, TFEB/MiTF activity.
Positive_regulation (resulting) of tryptase in mast cells associated with inflammation and microphthalmia
15) Confidence 0.03 Published 2007 Journal BMC Immunol Section Body Doc Link PMC2000913 Disease Relevance 0.75 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox